The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial / Guarneri, Valentina; Dieci, Maria V; Griguolo, Gaia; Miglietta, Federica; Girardi, Fabio; Bisagni, Giancarlo; Generali, Daniele G; Cagossi, Katia; Sarti, Samanta; Frassoldati, Antonio; Gianni, Lorenzo; Cavanna, Luigi; Pinotti, Graziella; Musolino, Antonino; Piacentini, Federico; Cinieri, Saverio; Prat, Aleix; Conte, Pierfranco. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 153:(2021), pp. 133-141-141. [10.1016/j.ejca.2021.05.018]
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
Musolino, AntoninoInvestigation
;
2021-01-01
Abstract
The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
